Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

被引：0

作者：

Kwiatek, Michal ^{[1
]}

Grosicki, Sebastian ^{[2
]}

Lopez Jimenez, Javier ^{[3
]}

Pinzon Marino, Sergio Felipe ^{[4
]}

Snauwaert, Sylvia ^{[5
]}

Kingsley, Edwin ^{[6
]}

Zacchetti, Giovanna ^{[7
]}

Wang, Ying ^{[8
]}

Wang, Luqiang ^{[8
]}

Depaus, Julien ^{[9
]}

机构：

[1] Ctr Med Pratia Poznan, Skorzewo, Poland

[2] Med Univ Silesia, Katowice, Poland

[3] Hosp Univ Ramon & Cajal, Madrid, Spain

[4] Hosp del Mar, Dept Clin Hematol, Barcelona, Spain

[5] Algemeen Ziekenhuis Sint Jan Brugge Oostende Camp, Brugge, Belgium

[6] Comprehens Canc Centers Nevada, Las Vegas, NV USA

[7] ADC Therapeut SA, Epalinges, Switzerland

[8] ADC Therapeut Amer Inc, Murray Hill, NJ USA

[9] Univ Catholique Louvain (UCL), Ctr Hosp Univ CHU, Namur Site Godinne, Yvoir, Belgium

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

aggressive B-cell lymphoma (ABCL); B cell; non-Hodgkin lymphoma; loncastuximab tesirine; rituximab; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-515

引用

页码：S439 / S440

页数：2

共 30 条

[21] Updated Results Confirm Favorable Outcome of Immunocompetent Patients with Primary CNS Lymphoma Treated By C5R Protocol in Combination with Intravenous Rituximab and Intrathecal Liposomal Cytarabine: A Multicentric Prospective Phase 2 Study of the Lymphoma Study Association (LYSA)
Ghesquieres, Herve
Tilly, Herve
Sonet, Anne
Dupuis, Jehan
Schwartzmann, Alexia
Nicolas-Virelizier, Emmanuelle
Andre, Marc
Trullemans, Fabienne
Fleck, Emmanuel
Boussetta, Sami
Morschhauser, Franck
Blay, Jean-Yves
BLOOD, 2014, 124 (21)
[22] OBINUTUZUMAB (GA101) OR RITUXIMAB (R) plus CHLORAMBUCIL (CLB) VERSUS CLB ALONE IN PATIENTS WITH CLL AND PRE-EXISTING MEDICAL CONDITIONS (COMORBIDITIES): FINAL STAGE 1 RESULTS OF THE CLL11 PHASE 3 TRIAL
Goede, V.
Fischer, K.
Humphrey, K.
Asikanius, E.
Busch, R.
Engelke, A.
Wendtner, C.
Samoylova, O.
Chagorova, T.
Dilhuydy, M.
De La Serna, J.
Illmer, T.
Opat, S.
Owen, C.
Kreuzer, K.
Langerak, A.
Ritgen, M.
Stilgenbauer, S.
Wenger, M.
Hallek, M.
HAEMATOLOGICA, 2013, 98 : 237 - 237
[23] MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial
Song, Yuqin
Yang, Haiyan
Jia, Youchao
Sheng, Lixia
Deng, Lijuan
Chen, Xi
Tang, Yongjing
Liu, Xifang
Liu, Sijun
Wei, Min
Li, Feng
BLOOD, 2024, 144 : 6481 - 6482
[24] Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
Yuqin Song
Hui Zhou
Huilai Zhang
Wei Liu
Yuerong Shuang
Keshu Zhou
Fangfang Lv
Hao Xu
Jianfeng Zhou
Wei Li
Huaqing Wang
Hongyu Zhang
Haiwen Huang
Qingyuan Zhang
Wei Xu
Zheng Ge
Ying Xiang
Shuye Wang
Da Gao
Shun’e Yang
Jinying Lin
Lin Wang
Liqun Zou
Meifang Zheng
Jing Liu
Zonghong Shao
Ying Pang
Ruixiang Xia
Zhendong Chen
Ming Hou
Hongxia Yao
Ru Feng
Zhen Cai
Mingzhi Zhang
Wenhua Ran
Lin Liu
Shan Zeng
Wei Yang
Peng Liu
Aibin Liang
Xuelan Zuo
Qingfeng Zou
Junxun Ma
Wei Sang
Ye Guo
Wei Zhang
Yongqing Cao
Yan Li
Jifeng Feng
Xin Du
Advances in Therapy, 2021, 38 : 1889 - 1903
[25] Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
Song, Yuqin
Zhou, Hui
Zhang, Huilai
Liu, Wei
Shuang, Yuerong
Zhou, Keshu
Lv, Fangfang
Xu, Hao
Zhou, Jianfeng
Li, Wei
Wang, Huaqing
Zhang, Hongyu
Huang, Haiwen
Zhang, Qingyuan
Xu, Wei
Ge, Zheng
Xiang, Ying
Wang, Shuye
Gao, Da
Yang, Shun'e
Lin, Jinying
Wang, Lin
Zou, Liqun
Zheng, Meifang
Liu, Jing
Shao, Zonghong
Pang, Ying
Xia, Ruixiang
Chen, Zhendong
Hou, Ming
Yao, Hongxia
Feng, Ru
Cai, Zhen
Zhang, Mingzhi
Ran, Wenhua
Liu, Lin
Zeng, Shan
Yang, Wei
Liu, Peng
Liang, Aibin
Zuo, Xuelan
Zou, Qingfeng
Ma, Junxun
Sang, Wei
Guo, Ye
Zhang, Wei
Cao, Yongqing
Li, Yan
Feng, Jifeng
Du, Xin
ADVANCES IN THERAPY, 2021, 38 (04) : 1889 - 1903
[26] Primary Results from Phase 3, Double-Blind, Placebo-Controlled SHINE Trial: Ibrutinib (Ibr) in Combination with Bendamustine-Rituximab (BR) and R-Maintenance as First-Line Treatment (1L) in Elderly Patients with Mantle Cell Lymphoma (MCL)
Dreyling, M.
Jurczak, W.
Jerkeman, M.
Trotman, J.
Zinzani, P. L.
Belada, D.
Boccomini, C.
Flinn, I. W.
Giri, P.
Goy, A.
Hamlin, P. A.
Hermine, O.
Hernandez-Rivas, J. -A
Hong, X.
Kim, S. J.
Lewis, D.
Mishima, Y.
Oezcan, M.
Perini, G. F.
Pocock, C.
Song, Y.
Spurgeon, S. E.
Storring, J. M.
Walewski, J.
Zhu, J.
Qin, R.
Henninger, T.
Deshpande, S.
Howes, A.
Le, Gouill S.
Wang, M. L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 149 - 150
[27] Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma
Thurner, Lorenz
Poeschel, Viola
Altmann, Bettina
Tilly, Herve
Andre, Marc
Maerevoet, Marie
Weber, Thomas
Hoffmann, Joerg
Dreyling, Martin
Maisonneuve, Herve
Kerkhoff, Andrea
Le Gouill, Steven
Stilgenbauer, Stephan
Ziepert, Marita
Houot, Roch
Haioun, Corinne
Held, Gerhard
BLOOD, 2020, 136
[28] Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
O'Reilly, Eileen Mary
Sahai, Vaibhav
Bendell, Johanna C.
Bullock, Andrea J.
LoConte, Noelle K.
Hatoum, Hassan
Ritch, Paul S.
Hool, Hugo
Leach, Joseph W.
Sanchez, James
Sohal, Davendra
Strickler, John H.
Patel, Ravindranath
Wang-Gillam, Andrea
Firdaus, Irfan
Kapoun, Ann M.
Holmgren, Eric
Zhou, Lei
Dupont, Jakob
Picozzi, Vincent J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[29] A RANDOMIZED MULTICENTRE PHASE III STUDY FOR FIRST LINE TREATMENT OF YOUNG PATIENTS WITH HIGH RISK (AAIPI 2-3) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RITUXIMAB (R) PLUS DOSE-DENSE CHEMOTHERAPY CHOP14/MEGACHOP14 WITH OR WITHOUT INTENSIFIED HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT). RESULTS OF DLCL04 TRIAL OF ITALIAN LYMPHOMA FOUNDATION (FIL)
Vitolo, U.
Chiappella, A.
Brusamolino, E.
Angelucci, E.
Balzarotti, M.
Carella, A. M.
Ciccone, G.
Gaidano, G.
Merli, F.
Pane, F.
Pavone, V.
Rossi, G.
Rigacci, L.
Stelitano, C.
Zaja, F.
Martelli, M.
ANNALS OF ONCOLOGY, 2011, 22 : 106 - 106
[30] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (FIT Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CIA, and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang" (GOELAMS): CLL2007FMP (for fit medically patients)
Lepretre, Stephane
Aurran, Therese
Mahe, Beatrice
Cazin, Bruno
Tournihlac, Olivier
Maisonneuve, Herve
Casasnovas, Olivier
Delmer, Alain
Leblond, Veronique
Royer, Bruno
Corront, Brigitte
Chevret, Sylvie
Delepine, Roselyne
Vaudaux, Sandrine
Van Den Neste, Eric
Bene, Marie-Christine
Cymbalista, Florence
Feugier, Pierre
BLOOD, 2009, 114 (22) : 225 - 225

← 1 2 3 →